TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03276624

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CABG
Description: surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
Study: NCT01173094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty
Description: Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: below-knee arterial bypass
Description: Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
Study: NCT00904137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast
Study: NCT03226821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
Study: NCT03861377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R2
Description: 0,7 microg/kg
Study: NCT00904137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splint

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape
Study: NCT03529669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™
Description: Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
Study: NCT01065883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker
Description: community health workers will provide education in the home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mailed information
Description: information will be mailed to the home on the same schedule as the experimental intervention
Study: NCT03747562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
Study: NCT03861377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R4
Description: 1,1 microg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R8
Description: 1,7 microg/kg
Study: NCT04013477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207
Description: DA-5207 Transdermal Delivery System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207
Description: DA-5207 Transdermal Delivery System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207
Description: DA-5207 Transdermal Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: donepezil HCl 10mg QD
Study: NCT04498832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
Study: NCT02348749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-MFBG (meta-fluoro benzylguanidine)
Description: About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging
Description: Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
Study: NCT00361348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study: NCT02882828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: switched from Prograf® to Envarsus®
Study: NCT00300898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervertebral electrothermal disc decompression (IDET)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Study: NCT01110876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
Study: NCT04398953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study: NCT01813708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Life-Style
Description: 16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Education
Description: 16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
Study: NCT02784197

Intervention type: DEVICE
Group type: OTHER
Intervention: Phase Signal Recorder
Description: The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
Study: NCT04200157

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete

Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete
Study: NCT04480125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100mg D1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg BIW PO
Study: NCT03168386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive motor rehabilitation
Description: Intensive motor rehabilitation during subacute stroke phase
Study: NCT03991819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
Study: NCT00642382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Agilus
Description: Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
Study: NCT03931720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT02088918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide/Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT03646201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FFF
Description: FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
Study: NCT01379391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Thrombopoietin (rHTPO)
Description: Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT.
Study: NCT00759291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acipimox
Description: 250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Study: NCT01808482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: 100 mg/mL GSK2618960
Description: 100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Dose of GSK2618960 decided from Part A
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B: matching placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: Dose of GSK2618960 decided from Part A and B
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
Study: NCT00815685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Description: Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
Study: NCT03560089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serious game
Description: Serious game with movements

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo serious game
Description: Serious game without movement
Study: NCT02286778

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acetogenins
Description: Acetogenins BID for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00406653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: abatacept
Description: \~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Study: NCT01005433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
Study: NCT02590809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment BX1514M
Description: X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 30 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walk distance test
Description: Walk distance test during 6 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk distance test
Description: Walk distance test during 6 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Study: NCT03650478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
Description: Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
Description: Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted